Therapeutics

Immunotherapy (passive)

Tools

Back to the Top
  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Immunotherapy (passive) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Aduhelm
Phase 3
Bapineuzumab
Phase 2, Phase 3
Crenezumab
Phase 2, Phase 3
Donanemab
Phase 2, Phase 3
Gamunex
Phase 2/3
Gantenerumab
Phase 2, Phase 2/3, Phase 3
Gosuranemab
Phase 2
Leqembi
Phase 1, Phase 2, Phase 3
Octagam®10%
Phase 2
Ponezumab
Phase 2
Solanezumab
Phase 2, Phase 2/3, Phase 3
Tilavonemab
Phase 2
Zagotenemab
Phase 2